Cargando…
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod
Fingolimod, an oral sphingosine 1-phosphate (S1P) receptor modulator, is approved for the treatment of relapsing forms of multiple sclerosis (MS). The interference with S1P signaling leads to retention particularly of chemokine receptor-7 (CCR7) expressing T cells in lymph nodes. The immunological b...
Autores principales: | Harrer, Andrea, Wipfler, Peter, Pilz, Georg, Oppermann, Katrin, Haschke-Becher, Elisabeth, Afazel, Shahrzad, Kraus, Jörg, Trinka, Eugen, Sellner, Johann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613283/ https://www.ncbi.nlm.nih.gov/pubmed/26378517 http://dx.doi.org/10.3390/ijms160921832 |
Ejemplares similares
-
Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab—A Flow Cytometric Study on Patients with Multiple Sclerosis
por: Harrer, Andrea, et al.
Publicado: (2012) -
Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study
por: Pilz, Georg, et al.
Publicado: (2019) -
Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
por: Pilz, Georg, et al.
Publicado: (2020) -
The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF
por: Harrer, Christine, et al.
Publicado: (2021) -
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
por: Moser, Tobias, et al.
Publicado: (2021)